Study S001635

A Single-centre, Randomised, Double-blind Two-period Cross-over Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT02079870
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 30
Start: 2014-03-06
Primary completion: 2015-01-07
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Metabolism and Nutrition Disorder; Obesity
Interventions: DRUG:semaglutide; DRUG:placebo
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2013-000012-24; OTHER:U1111-1138-2039

Registered primary outcomes

Ad libitum energy intake during a lunch meal (following a standardised breakfast meal) [After 12 weeks of treatment]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0025109	Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Hjerpsted JB, Diabetes, obesity & metabolism	2018	Randomized trial	PMID 28941314 DOI	registry reference RESULT:28941314
R0025356	Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Blundell J, Diabetes, obesity & metabolism	2017	Randomized trial	PMID 28266779 DOI	registry reference RESULT:28266779